Abstract
Androgen deprivation therapy (ADT) is a major component of the contemporary management of prostate cancer. ADT's use is increasing rapidly. The side effects of this therapy include loss of bone mass and fractures, increase in fat mass, and worsening of insulin resistance, the metabolic syndrome, diabetes and cardiovascular risk, and anemia and loss of muscle. Neuropsychological and sexual symptoms are common. The impact of these side effects is often overlooked or underestimated in decisions about prostate cancer therapy. This review surveys the data relating to the side effects of ADT and provides recommendations regarding their minimization and management.
Copyright © 2011. Published by Elsevier Inc.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Androgen Antagonists / adverse effects*
-
Androgen Antagonists / therapeutic use*
-
Animals
-
Antineoplastic Agents, Hormonal / adverse effects
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Carcinoma / drug therapy*
-
Carcinoma / epidemiology
-
Carcinoma / metabolism
-
Carcinoma / physiopathology
-
Cardiovascular Physiological Phenomena / drug effects
-
Dietary Supplements / statistics & numerical data
-
Drug-Related Side Effects and Adverse Reactions / epidemiology
-
Drug-Related Side Effects and Adverse Reactions / therapy*
-
Humans
-
Life Style
-
Male
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / epidemiology
-
Prostatic Neoplasms / metabolism
-
Prostatic Neoplasms / physiopathology
Substances
-
Androgen Antagonists
-
Antineoplastic Agents, Hormonal